title: [Refractory subacute cutaneous lupus erythematosus treated with rituximab].
authors.forename: D E
authors.initials: DE
authors.lastname: Cieza-Díaz
authors.forename: J A
authors.initials: JA
authors.lastname: Avilés-Izquierdo
authors.forename: C
authors.initials: C
authors.lastname: Ceballos-Rodríguez
authors.forename: R
authors.initials: R
authors.lastname: Suárez-Fernández
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy*; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012074:Remission Induction; D000069283:Rituximab; D013792:Thalidomide / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000927:Anticonvulsants; D000962:Antimalarials; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000069283:Rituximab; D013792:Thalidomide; D000068800:Etanercept; D011241:Prednisone